 |
66 Diseases |  |
138 Trials |
|
138 Trials |  |
1390 News |  |
| «12345678910111213...2122» |
- || Nubeqa (darolutamide) / Bayer, Orion Corp
Trial primary completion date: EORTC-1532: ODM-201 vs Androgen Deprivation Therapy in Hormone na (clinicaltrials.gov) - Sep 7, 2023
P2, N=61, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Dec 2022 --> Dec 2023
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial initiation date, Combination therapy, Circulating tumor DNA, Metastases: SAFIR 03: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib (clinicaltrials.gov) - Sep 6, 2023
P2, N=162, Not yet recruiting, Sponsor: UNICANCER
Trial primary completion date: Dec 2022 --> Dec 2023 Initiation date: Jun 2023 --> Nov 2023
- | Enrollment open: OFSET: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (clinicaltrials.gov) - Sep 5, 2023
P3, N=3960, Recruiting, Sponsor: NRG Oncology
Initiation date: Jun 2023 --> Nov 2023 Not yet recruiting --> Recruiting
- | Trial completion date, Trial primary completion date: GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET (clinicaltrials.gov) - Aug 30, 2023
P3, N=784, Recruiting, Sponsor: The University of Hong Kong
Not yet recruiting --> Recruiting Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie
Hidradenitis suppurativa in transgender patients: a case series (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2187;
Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 A 48-year-old transgender woman (assigned male at birth (AMAB)), with personal history of Crohn
- ||| triptorelin / Generic mfg.
P3 data, Journal: Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase (Pubmed Central) - Aug 16, 2023
P3
The triptorelin 3-month PR formulation demonstrated similar efficacy to that previously reported in non-Chinese patients with CPP and had an acceptable safety profile. This supports triptorelin 3-month PR as a viable option for Chinese children with CPP.
- | Orserdu (elacestrant) / Menarini
New P2 trial: SOLTI-2104: Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (clinicaltrials.gov) - Aug 8, 2023
P2, N=48, Not yet recruiting, Sponsor: SOLTI Breast Cancer Research Group
- | Cetrotide (cetrorelix) / EMD Serono
New P3 trial: Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes (clinicaltrials.gov) - Aug 2, 2023
P3, N=387, Recruiting, Sponsor: Beni-Suef University
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Choriomon (human choriomon gonadotropin (hCG)) / IBSA Institute Biochemical SA
New trial: HCG Levels After Ovulation Triggering as Predictors of ICSI Outcome (clinicaltrials.gov) - Aug 1, 2023
P=N/A, N=100, Completed, Sponsor: Mansoura University
- | Zomacton (somatropin) / Ferring
Trial completion date, Trial primary completion date, Combination therapy: ZomaTrip: A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height (clinicaltrials.gov) - Jul 31, 2023
P4, N=44, Active, not recruiting, Sponsor: Belgian Study Group for Pediatric Endocrinology
This supports triptorelin 3-month PR as a viable option for Chinese children with CPP. Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date: DUAL-T: Dual Trigger for Elective Fertility Preservation (clinicaltrials.gov) - Jul 27, 2023
P4, N=136, Completed, Sponsor: Fundaci
Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Jan 2023 --> Jan 2024 Recruiting --> Completed | N=100 --> 136 | Trial completion date: Jun 2024 --> Apr 2023 | Trial primary completion date: Dec 2023 --> Apr 2023
- | clomifene citrate / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Mild Stimulation Protocol Using Clomiphene Citrate for Women With PCOS Undergoing in Vitro Fertilization (clinicaltrials.gov) - Jul 20, 2023
P4, N=154, Active, not recruiting, Sponsor: American University of Beirut Medical Center
Recruiting --> Completed | N=100 --> 136 | Trial completion date: Jun 2024 --> Apr 2023 | Trial primary completion date: Dec 2023 --> Apr 2023 Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Jul 2025 | Trial primary completion date: Jul 2022 --> Jan 2025
- | Trial completion: The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies (clinicaltrials.gov) - Jul 20, 2023
P4, N=277, Completed, Sponsor: American University of Beirut Medical Center
Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Jul 2025 | Trial primary completion date: Jul 2022 --> Jan 2025 Recruiting --> Completed
- | anastrozole / Generic mfg., triptorelin / Generic mfg.
Journal: Sex steroids regulate liver fat content and body fat distribution in both men and women: a study in transgender persons. (Pubmed Central) - Jul 18, 2023
Recruiting --> Completed Sex hormones regulate liver fat content and visceral fat in men and women.
- | goserelin acetate / Generic mfg., megestrol / Generic mfg., triptorelin / Generic mfg.
New trial: Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer (clinicaltrials.gov) - Jul 14, 2023
P=N/A, N=57, Recruiting, Sponsor: Peking University People's Hospital
- | triptorelin / Generic mfg.
Journal: Eosinophilic Dermatitis due to Triptorelin Pamoate in a Patient with Prostate Cancer Confirmed by Patch Testing. (Pubmed Central) - Jul 10, 2023
Sex hormones regulate liver fat content and visceral fat in men and women. No abstract available
- | triptorelin / Generic mfg.
Journal: Triptorelin nanoparticle-loaded microneedles for use in assisted reproductive technology. (Pubmed Central) - Jul 4, 2023
Surging levels of luteinizing hormone and estradiol in plasma and their subsequent prolonged downregulation indicate the potential therapeutic role of NPs-MNs in ART regimens. The triptorelin-loaded NPs-MNs developed in this study may reduce the physical and psychological burden of pregnant women using ART regimens.
- | triptorelin / Generic mfg.
Preclinical, Journal: The Finding of New In Vivo Metabolite Triptorelin (5-10) in Human Urine Using Liquid Chromatography Coupled with Ion Trap/Time-of-Flight Mass Spectrometry with Dimethyl Sulfoxide Additives in the Mobile Phase. (Pubmed Central) - Jul 2, 2023
The structure of the metabolite, triptorelin (5-10), is proposed from bottom-up mass spectrometry analysis. The discovery of in vivo triptorelin (5-10) can possibly be used as supporting evidence of triptorelin misuse in athletes.
- | triptorelin / Generic mfg.
Journal: Endocrine responses to triptorelin in healthy women, women with Polycystic Ovary Syndrome and Hypothalamic Amenorrhea. (Pubmed Central) - Jun 19, 2023
The discovery of in vivo triptorelin (5-10) can possibly be used as supporting evidence of triptorelin misuse in athletes. FSH response to triptorelin was attenuated in women with polycystic ovaries, both with and without ovarian stimulation, and was negatively related to AMH levels.
- |||| Erleada (apalutamide) / J&J
Trial primary completion date: PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (clinicaltrials.gov) - Jun 18, 2023
P3, N=412, Recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
FSH response to triptorelin was attenuated in women with polycystic ovaries, both with and without ovarian stimulation, and was negatively related to AMH levels. Trial primary completion date: Jan 2028 --> Jan 2030
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Preclinical, Journal: LCZ696 (sacubitril/valsartan) mitigates cyclophosphamide-induced premature ovarian failure in rats; the role of TLR4/NF-?B/NLRP3/Caspase-1 signaling pathway. (Pubmed Central) - Jun 16, 2023
Trial primary completion date: Jan 2028 --> Jan 2030 LCZ696 effectively mitigated CP-induced POF, offering promising protection that could be related to its suppression power on NLRP3-induced pyroptosis and TLR4/NF-B P65 pathway.
- | triptorelin / Generic mfg.
Trial completion, Trial completion date: The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response (clinicaltrials.gov) - Jun 15, 2023
P=N/A, N=52, Completed, Sponsor: Royan Institute
LCZ696 effectively mitigated CP-induced POF, offering promising protection that could be related to its suppression power on NLRP3-induced pyroptosis and TLR4/NF-B P65 pathway. Recruiting --> Completed | Trial completion date: May 2022 --> Nov 2022
- ||||| giredestrant (GDC-9545) / Roche
New P2 trial: PREcoopERA: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer (clinicaltrials.gov) - Jun 9, 2023
P2, N=220, Not yet recruiting, Sponsor: ETOP IBCSG Partners Foundation
- | enzalutamide capsule / Generic mfg.
Journal, Metastases: Myocardial bridge in a patient with castration-resistant metastatic prostate cancer treated with enzalutamide. (Pubmed Central) - Jun 7, 2023
Due to the high prevalence of prostate cancer in elderly patients at high cardiovascular risk and the increasing use of androgen receptor-targeted agent, a multidisciplinary approach is highly recommended to weigh survival benefits on toxicities. This case report may support the use of androgen receptor-targeted agent in elderly patients with controlled cardiovascular diseases, a population that is often excluded from randomised trials.
- | leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
Journal: Leuprolide and triptorelin treatment in children with idiopathic central precocious puberty: an efficacy/tolerability comparison study. (Pubmed Central) - Jun 2, 2023
Moreover, the onset of side effects appearance related to GnRHa therapy significantly reduces with the increase of the initial bone age (p?=?0.038). Leuprolide and triptorelin treatment appear to be effective and safe without significant difference between the two drugs in term of efficacy and tolerability, making both good options for treating CPP.
- || Biomarker, Trial completion date, Trial primary completion date: BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov) - Jun 2, 2023
P2, N=550, Recruiting, Sponsor: Hoffmann-La Roche
Leuprolide and triptorelin treatment appear to be effective and safe without significant difference between the two drugs in term of efficacy and tolerability, making both good options for treating CPP. Trial completion date: Sep 2026 --> Dec 2028 | Trial primary completion date: Aug 2024 --> Dec 2026
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment closed, Trial primary completion date, Surgery: STEEL: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery (clinicaltrials.gov) - Jun 2, 2023
P2, N=188, Active, not recruiting, Sponsor: RTOG Foundation, Inc.
Trial completion date: Sep 2026 --> Dec 2028 | Trial primary completion date: Aug 2024 --> Dec 2026 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2024 --> Apr 2023
- | NN1213 / Novo Nordisk
Trial primary completion date, Metastases: EORTC-1206: Androgen Deprivation Therapy in Advanced Salivary Gland Cancer (clinicaltrials.gov) - Jun 1, 2023
P2, N=149, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2024 --> Apr 2023 Trial primary completion date: Mar 2023 --> Jun 2023
- | New P3 trial: OFSET: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (clinicaltrials.gov) - May 30, 2023
P3, N=3960, Not yet recruiting, Sponsor: NRG Oncology
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion date: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - May 25, 2023
P2, N=19, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Mar 2023 --> Jun 2023 Trial completion date: Apr 2023 --> Apr 2024
- || triptorelin / Generic mfg.
Trial completion date, Trial primary completion date, HEOR: ROSE: Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment (clinicaltrials.gov) - May 23, 2023
P=N/A, N=419, Recruiting, Sponsor: Ipsen
Trial completion date: Apr 2023 --> Apr 2024 Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Jun 2024
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date, HEOR, Real-world evidence, Real-world, Metastases: Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland (clinicaltrials.gov) - May 18, 2023
P=N/A, N=1, Recruiting, Sponsor: Pfizer
Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Jun 2024 Trial primary completion date: Apr 2023 --> Nov 2023
- | Cetrotide (cetrorelix) / EMD Serono
Enrollment open, Trial completion date, Trial primary completion date: DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation (clinicaltrials.gov) - May 18, 2023
P1/2, N=30, Recruiting, Sponsor: Universitair Ziekenhuis Brussel
Trial primary completion date: Apr 2023 --> Nov 2023 Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Dec 2025 | Trial primary completion date: Nov 2021 --> Nov 2025
- | triptorelin / Generic mfg.
Enrollment open, Phase classification, Trial completion date, Trial primary completion date: Coimbra: Combining Interventions of Fertility Preservation to Mitigate Fertility Loss After Breast Cancer (clinicaltrials.gov) - May 18, 2023
P=N/A, N=41, Recruiting, Sponsor: Universitair Ziekenhuis Brussel
Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Dec 2025 | Trial primary completion date: Nov 2021 --> Nov 2025 Unknown status --> Recruiting | Phase classification: P2 --> PN/A | Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Nov 2021 --> Nov 2024
- Gnrh Agonist Therapy Induced Aggression in Children. a Case Report (Hall B Foyer, Exhibition Level Moscone South) - May 17, 2023 - Abstract #APA2023APA_1358;
Even though the use of GnRHa has shown to be effective in the treatment of psychosis, hallucinations, and emotional lability, it might actually be a catalyst for a host of emotional and psychiatric disturbances as seen in our patient. This highlights the need for more research to be done in this area and a collaborative health professional approach to better understand and treat various impacts of GnRHa therapy.
- || triptorelin / Generic mfg.
PK/PD data, Journal: Effects of water-soluble additive on the release profile and pharmacodynamics of triptorelin loaded in PLGA microspheres. (Pubmed Central) - May 16, 2023
Morphologic change was reflected in the gradual closure of the pores. This was the reason that drug release slowed down after the initial burst.
- | Trial completion date, Trial primary completion date: DUAL-T: Dual Trigger for Elective Fertility Preservation (clinicaltrials.gov) - May 15, 2023
P4, N=100, Recruiting, Sponsor: Fundaci
This was the reason that drug release slowed down after the initial burst. Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Dec 2023
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: T-TRANSPORT: Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial (clinicaltrials.gov) - May 15, 2023
P3, N=400, Recruiting, Sponsor: Institut Universitari Dexeus
Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Dec 2023 Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- ||| Elonva (corifollitropin alfa) / Organon
Trial completion, Trial primary completion date: DUO_STIM_FRESH: Double Stimulation Followed by a Fresh Embryo Transfer (clinicaltrials.gov) - May 15, 2023
P4, N=120, Completed, Sponsor: Fundaci
Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Recruiting --> Completed | Trial primary completion date: Oct 2022 --> Jan 2023
- | triptorelin / Generic mfg.
Observational data, Journal: Female BMI and Body Weight Is Not Associated with Oocyte Yield and Maturation in hCG, Agonist or Dual Trigger Cycles: A Large Observational Study including 5000 Cycles. (Pubmed Central) - May 13, 2023
Recruiting --> Completed | Trial primary completion date: Oct 2022 --> Jan 2023 Our study demonstrates that, independent of the type of trigger, patients' BMI and weight are not associated with oocyte yield, maturation, or FOI.
- ||| abiraterone acetate / Generic mfg., triptorelin / Generic mfg.
GP wasn't involved at that stage Tony just the urologist when he prescribed Triptorelin. The same thing happened when I saw the oncologist later and he put me on Abiraterone also. It my one big gripe with the system. Should have got an info pack at least. I did my own research. (Twitter) - May 11, 2023
- | Trial completion date, Trial primary completion date: GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET (clinicaltrials.gov) - May 10, 2023
P3, N=784, Recruiting, Sponsor: The University of Hong Kong
Our study demonstrates that, independent of the type of trigger, patients' BMI and weight are not associated with oocyte yield, maturation, or FOI. Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Mar 2023 --> Sep 2023
- | Ovidrel (choriogonadotropin alfa) / EMD Serono, Menopur (menotropin) / Ferring, Cetrotide (cetrorelix) / EMD Serono
Trial completion, Phase classification, Trial completion date: CS-EOSP-ICSI: Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility (clinicaltrials.gov) - May 9, 2023
P1/2, N=200, Completed, Sponsor: Lebanese University
Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Mar 2023 --> Sep 2023 Active, not recruiting --> Completed | Phase classification: PN/A --> P1/2 | Trial completion date: Dec 2021 --> May 2023
- |||| triptorelin / Generic mfg.
New P2 trial: DEFINE: Dose Escalation For INtraprostatic LEsions (clinicaltrials.gov) - May 8, 2023
P2, N=54, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
- | progesterone / Generic mfg., triptorelin / Generic mfg.
New trial: Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates (clinicaltrials.gov) - May 1, 2023
P=N/A, N=144, Recruiting, Sponsor: Shaare Zedek Medical Center
- Cardiovascular comorbidities and cardiovascular events in patients with metastatic prostate cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_6039;
Addition of abiraterone to ADT increase the risk of cardiovascular events. Physicians should monitor their patients in order to early detect any abnormality, and should encourage them to adopt a healthier lifestyle.
- Firmagon (degarelix) / Astellas, Ferring
Propensity score matched analysis of major adverse cardiac events in patients with localized prostate cancer receiving short term vs long term ADT. (On Demand | Hall A; Poster Bd # 464) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3690;
Patients were defined as receiving ADT if they received leuprolide, goserelin, bicalutamide, triptorelin, degarelix, flutamide, or nilutamide. In a national dataset analysis of patients with local PrCa and no history of MACE or abiraterone or docetaxel within 3 months of diagnosis LT-ADT was associated with increased odds of CAD but there was no difference in the composite endpoint of MACE or metastatic recurrence.
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
Enrollment open: URONCOR 06-24: Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624 (clinicaltrials.gov) - Apr 24, 2023
P3, N=534, Recruiting, Sponsor: Grupo de Investigaci
In a national dataset analysis of patients with local PrCa and no history of MACE or abiraterone or docetaxel within 3 months of diagnosis LT-ADT was associated with increased odds of CAD but there was no difference in the composite endpoint of MACE or metastatic recurrence. Not yet recruiting --> Recruiting
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment open, Enrollment change, HEOR, Real-world evidence, Real-world, Metastases: Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland (clinicaltrials.gov) - Apr 19, 2023
P=N/A, N=1, Recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=15000 --> 1
- | triptorelin / Generic mfg., bicalutamide / Generic mfg.
Trial primary completion date: SPA: SRT Versus SRT+ADT in Prostate Cancer (clinicaltrials.gov) - Apr 18, 2023
P3, N=310, Recruiting, Sponsor: Marco Lorenzo Bonu
Not yet recruiting --> Recruiting | N=15000 --> 1 Trial primary completion date: Dec 2024 --> Dec 2025